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The adjuvanted hepatitis B vaccine, HB-AS04, elicits more
rapid and persistent protective antibody concentrations than
double doses of conventional recombinant vaccines in
patients with renal insufficiency. We compared the
immunogenicity, reactogenicity, and safety of the
AS02V-adjuvanted hepatitis B vaccine HB-AS02 with that
of HB-AS04. In this phase III, open, randomized study, 151
hepatitis B vaccine-naı¨ve pre-dialysis, peritoneal dialysis, and
hemodialysis patients aged 15 years and older received three
doses of HB-AS02 at 0, 1, and 6 months. Another 149 similar
patients received four doses of HB-AS04 at 0, 1, 2, and 6
months, and all were followed up for 12 months. HB-AS02
elicited more rapid and persistent seroprotection than HB-
AS04, with rates of 77 and 39%, respectively, 1 month after
the second vaccine dose, and 94 and 79%, respectively,
at 12 months. Superiority of HB-AS02 over HB-AS04 in
anti-hepatitis B geometric mean concentrations was found
at all time points. HB-AS02 was more reactogenic than
HB-AS04, but adverse events were mainly transient, of mild
to moderate intensity with no reportable vaccine-related
serious events. We conclude that a three-dose primary course
of HB-AS02 induced more rapid, enhanced, and persistent
protection in patients with renal insufficiency than the licensed
four-dose primary schedule of HB-AS04. This adjuvanted
vaccine affords greater protection with reduced need for
booster doses in patients at high risk of hepatitis B infection.
Kidney International (2010) 77, 247–255; doi:10.1038/ki.2009.454;
published online 25 November 2009
KEYWORDS: adjuvant; HB-AS02 vaccine; HB-AS04 vaccine; hemodialysis;
hepatitis B; vaccination
Hepatitis B virus (HBV) infection is a serious global health
problem, with up to 2 billion people infected worldwide and
more than 350 million chronic carriers.1,2 The prevalence of
viral hepatitis is higher in dialysis patients than in the general
population because of the opportunity for exposure during
the dialysis procedure.3 The importance of HBV vaccination
in patients requiring dialysis is recognized in most indus-
trialized countries. The Centers for Disease Control and
Prevention recommends that all dialysis patients should be
vaccinated against HBV, with vaccination also recommended
for pre-end-stage renal disease patients before they become
dependent on dialysis.4,5 Uremic patients who are candidates
for kidney transplantation should also be vaccinated against
HBV before transplantation.6 However, patients with renal
insufficiency have an impaired immune response to conven-
tional recombinant HBV vaccines when compared with
healthy individuals.7–9 Consequently, it is usually recom-
mended to use double doses of conventional recombinant
HBV vaccine in dialysis patients, with administration of a
fourth vaccine dose typically necessary to increase the
seroprotection rate.4 Despite this reinforced vaccination
schedule, conventional recombinant HBV vaccines induce
lower and less persistent seroprotection rates in uremic
patients compared with healthy subjects.10,11
One approach to improve the immunogenicity of existing
HBV vaccines is adjuvantation. An adjuvanted HBV vaccine
HB-AS04 (FENDrix; GlaxoSmithKline (GSK) Biologicals,
Rixensart, Belgium) was licensed in Europe in 2005 for
active immunization against HBV for patients with renal
insufficiency (including pre-hemodialysis and hemodialysis
patients) aged over 15 years.12 HB-AS04 consists of
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recombinant hepatitis B surface antigen (HBsAg) formulated
with aluminum phosphate and monophosphoryl lipid
(MPL), a purified, detoxified derivative of the lipopolysac-
charide molecule of the bacterial wall of Salmonella
minnesota.13 Results of clinical studies show HB-AS04 to
elicit higher and more persistent levels of anti-HBs antibodies
than double doses of a conventional recombinant HBV
vaccine when administered according to a 0-, 1-, 2-, and
6-month schedule.14–17
HB-AS02 is an adjuvanted HBV vaccine containing
recombinant HBsAg formulated with AS02 instead of AS04.
AS02 is an oil-in-water emulsion-based adjuvant system
consisting of MPL and QS21, a highly purified immunosti-
mulant extracted from the bark of the South American
Quillaja saponaria tree.13 HB-AS02 does not contain any
aluminum salt and is formulated without any preservative.
HB-AS02 administered according to a 0-, 1-, and 10-month
schedule has been shown to elicit strong and persistent
antibody responses against HBsAg in healthy adult volun-
teers.18 All subjects were seroprotected after two vaccine
doses, with a geometric mean anti-HBs antibody concentra-
tion (GMC) of approximately 8000mIU/ml.18
This study was undertaken to assess whether HB-AS02
would be associated with enhanced immunogenicity in the
end-stage renal disease population and to evaluate whether it
could be adequately immunogenic in this population using a
three-dose primary schedule compared with the licensed
four-dose primary schedule of HB-AS04.
RESULTS
Study population characteristics
A total of 300 subjects were enrolled between 23 February 2006
and 14 July 2006 and received at least one dose of the study
vaccine (151 in the HB-AS02 group and 149 in the HB-AS04
group). The two groups were similar in terms of baseline
demographic characteristics (Table 1). Mean (±s.d.) age of
study participants was 63.5±14.1 years, 58.0% were male, and
the population was predominantly Caucasian/European
(98.3%). The two groups were also well matched in terms of
dialysis status, with 44% of study participants undergoing
hemodialysis, 42% pre-dialysis, and 14% peritoneal dialysis.
A total of 34 subjects were withdrawn from the primary
vaccination study before the month 7 visit (10 in the HB-
AS02 group and 24 in the HB-AS04 group). A total of 242
subjects returned for the month 12 visit (125 and 117 in the
two groups, respectively). The reasons for withdrawal from
the study over time are summarized in Figure 1.
Immunogenicity
The onset of protection was faster in the HB-AS02 group
than in the HB-AS04 group (Table 2). At month 2, 1 month
after the second vaccine dose, the seroprotection rate was
77.0% in the HB-AS02 group and 39.0% in the HB-AS04
group. The lower limit of the standardized asymptotic 95%
confidence interval (CI) on the difference in seroprotection
rates between the two groups was 40 (the difference in
seroprotection rate was 38.06%; 95% CI 27.01–48.17),
showing the superiority of HB-AS02 over HB-AS04 in terms
of seroprotection rate. As shown in Figure 2, the percentage
of subjects with anti-HBs antibody concentration
X100mIU/ml at month 2 was also higher in the HB-AS02
group (55.4% compared with 16.2% in the HB-AS04 group).
The HB-AS02 vaccine was also superior to the HB-AS04
vaccine in terms of seroprotection rates at 1 month after the
second vaccine dose in the HB-AS02 group (month 2)
compared with 1 month after the third vaccine dose in the
HB-AS04 group (month 3) (77.0 versus 64.9%, respectively;
difference in seroprotection rate, 12.10%; 95% CI
1.53–22.58). Superiority was also observed when comparing
the two groups at months 1, 3, and 6 (Table 2). At month 6
(that is, after two doses in the HB-AS02 group and three
doses in the HB-AS04 group), seroprotection rates were 88.2
and 70.4% in the two groups, respectively. The percentage of
Table 1 | Demographic characteristics of the total vaccinated
cohort
HB-AS02
(n¼151)
HB-AS04
(n¼149)
Total
(n¼300)
Age, years
Mean (±s.d.) 64.1 (±13.3) 62.9 (±14.8) 63.5 (±14.1)
Gender, N (%)
Male 83 (55.0) 91 (61.1) 174 (58.0)
Female 68 (45.0) 58 (38.9) 126 (42.0)
Race, N (%)
Caucasian/European 149 (98.7) 148 (98.0) 295 (98.3)
Arabic/North African 0 (0.0) 2 (1.3) 2 (0.7)
African/African
American
1 (0.7) 1 (0.7) 2 (0.7)
Asian 1 (0.7) 0 (0.0) 1 (0.3)
Reason for renal failure, N (%)a
Polycystic renal
disease
4 (2.6) 9 (6.0) 13 (4.3)
Glomerular disease 18 (11.9) 19 (12.8) 37 (12.3)
Nephroangiosclerosis 41 (27.2) 53 (35.6) 94 (31.3)
Diabetic
nephropathy
48 (31.8) 32 (21.5) 80 (26.7)
Interstitial disease 38 (25.2) 22 (14.8) 60 (20.0)
Other 26 (17.2) 28 (18.8) 54 (18.0)
Etiology unknown 5 (3.3) 9 (6.0) 14 (4.7)
Dialysis status, N (%)
Pre-dialysis 64 (42.4) 62 (41.6) 126 (42.0)
Peritoneal dialysis 22 (14.6) 20 (13.4) 42 (14.0)
Hemodialysis 65 (43.0) 67 (45.0) 132 (44.0)
Diabetes type, N (%)
Type I 4 (2.7) 2 (1.4) 6 (2.1)
Type II 62 (41.1) 56 (37.6) 118 (39.3)
Hepatitis C virus (HCV) status, N (%)
Positive 1 (0.7) 4 (2.7) 5 (1.7)
Negative 122 (80.8) 121 (81.2) 243 (81.0)
Not tested/unknown 28 (18.5) 24 (16.1) 52 (17.3)
Abbreviations: HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02;
HB-AS04, HBV vaccine adjuvanted with AS04.
aSubjects may have more than one reason for renal failure.
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subjects with anti-HBs antibody concentration of
X100mIU/ml at this time was 61.8% in the HB-AS02 group
and 44.0% in the HB-AS04 group (Figure 2). At month 7
(that is, 1 month after completion of the three-dose
vaccination course in the HB-AS02 group and the four-dose
vaccination course in the HB-AS04 group), seroprotection
rates were 96.4 and 91.8% in the two groups, respectively.
This difference was not statistically significant. However, the
Total enrolled and vaccinated
(n = 300)
HB-AS02
(n =151)
Month 0 (n =151) Month 0 (n =149)
Month 1 (n =150) Month 1 (n =143)
Month 2 (n =139)Month 2 (n =148)
Month 3 (n =147) Month 3 (n =136)
Month 6 (n =127)Month 6 (n =145)
Month 7 (n =141)
Month 12 (n =125) Month 12 (n =117)
Month 7 (n =125)
6 Subjects withdrawn:
   5 protocol violations
   1 non-fatal SAE
1 Subject withdrawn:
1 consent withdrawal
2 Subjects withdrawn:
   1 non-fatal SAE
   1 fatal SAE
1 Subject withdrawn:
   1 non-fatal SAE
2 Subjects withdrawn:
   1 protocol violation
   1 fatal SAE
4 Subjects withdrawn:
   3 fatal SAEs
   1 incomplete vaccination
16 Subjects withdrawn:
  10 deaths**
  1 consent withdrawal
  2 lost to follow-up
  2 incomplete vaccination
  1 palliative care
4 Subjects withdrawn:
   3 protocol violations
   1 non-serious AE
3 Subjects withdrawn:
   1 protocol violation
   1 non-serious AE
   1 fatal SAE
9 Subjects withdrawn:
   1 non-fatal SAE
   6 fatal SAEs
   1 non-serious AE
   1 kidney transplantation
2 Subjects withdrawn:
   1 non-fatal SAE
   1 incomplete vaccination
7 Subjects withdrawn:
   4 deaths**
   2 lost to follow-up
   1 incomplete vaccination
1 Subject withdrawn:
    1 fatal SAE*
HB-AS04
(n =149)
Figure 1 | Subject flowchart. HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with
AS04. *This fatal serious adverse event (SAE) started during the primary vaccination study and the subject died the day after the month 7
visit. **These events were not classed as fatal SAEs, as they occurred out of study.
Table 2 | Proportion of subjects seroprotected (anti-HBs antibodies X10mIU/ml) (total vaccinated cohort)
HB-AS02 HB-AS04
Difference in seroprotection rate
(HB-AS02 minus HB-AS04)
Month Dose n % 95% CI Dose n % 95% CI % 95% CI
Pre Pre 150 0.7 0.0–3.7 Pre 148 3.4 1.1–7.7 — —
M1 PI 150 18.0 12.2–25.1 PI 142 7.7 3.9–13.4 10.25 2.64–18.10
M2 PII 148 77.0 69.4–83.5 PII 136 39.0 30.7–47.7 38.06 27.01–48.17
M3 PII 146 82.9 75.8–88.6 PIII 134 64.9 56.2–73.0 17.95 7.77–28.03
M6 PII 144 88.2 81.8–93.0 PIII 125 70.4 61.6–78.2 17.79 8.28–27.51
M7 PIII 137 96.4 91.7–98.8 PIV 122 91.8 85.4–96.0 4.55 1.25–11.22
M12 PIII 125 93.6 87.8–97.2 PIV 117 78.6 70.1–85.7 14.97 6.53–24.02
Abbreviations: CI, confidence interval; HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with AS04.
n is the number of subjects with available results.
% is the percentage of subjects with anti-HBs antibody concentration of X10mIU/ml.
Criterion for superiority is the lower limit of the 95% standardized asymptotic confidence interval on the difference in seroprotection rate 40.
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percentage of subjects with anti-HBs antibody concentration
of X100mIU/ml at month 7 was superior in the HB-AS02
group than in the HB-AS04 group (91.2% compared with
74.6%, respectively; difference in seroprotection rate, 16.65%;
95% CI 7.70–26.01; Figure 2).
The immune response elicited by HB-AS02 not only
started earlier, but it also persisted longer (Table 2 and
Figure 2). At month 12 (that is, 6 months after completion of
the three-dose vaccination course in the HB-AS02 group and
the four-dose vaccination course in the HB-AS04 group),
93.6% of subjects in the HB-AS02 group remained
seroprotected compared with 78.6% of those in the HB-
AS04 group. The percentage of subjects with anti-HBs
antibody concentration of X100mIU/ml at this time was
also superior in the HB-AS02 group (86.4 versus 64.1% in the
HB-AS04 group; difference in seroprotection rate, 22.30%;
95% CI 11.63–32.82).
In terms of anti-HBs GMCs (Table 3 and Figure 3),
superiority of HB-AS02 over HB-AS04 was observed at all
time points. Superiority of the HB-AS02 vaccine over HB-
AS04 was also observed in terms of GMC at 1 month after the
second vaccine dose in the HB-AS02 group (month 2)
compared with 1 month after the third vaccine dose in the
HB-AS04 group (month 3) (83.0 versus 40.1, respectively;
GMC ratio, 2.07; 95% CI 1.11–3.87). At month 7, anti-HBs
GMCs were 415-fold higher in the HB-AS02 group than in
the HB-AS04 group (10,401.9 and 666.8mIU/ml, respec-
tively). Anti-HBs GMCs remained 421-fold higher in the
HB-AS02 group than in the HB-AS04 group at month 12
(2510.1 and 118.4mIU/ml, respectively).
The HB-AS02 vaccine elicited a strong and persistent
immune response regardless of the dialysis status of the
vaccinee (Table 4). For all three dialysis status subgroups
(pre-dialysis, peritoneal dialysis, and hemodialysis), seropro-
tection rates at month 2 were superior in the HB-AS02
subgroups than in the HB-AS04 subgroups (72.7–79.4%
versus 36.2–41.7%, respectively), with anti-HBs GMCs 7- to
23-fold higher in the HB-AS02 subgroups. At month 7,
seroprotection rates were high for both vaccines in all
subgroups (X86.8%); however, anti-HBs GMCs were 9- to
32-fold higher in the HB-AS02 subgroups. Seroprotection
rates, the proportion of subjects with anti-HBs antibodies of
X100mIU/ml, and anti-HBs GMCs at month 12 were higher
in patients vaccinated with HB-AS02 than in those who
received HB-AS04 in all subgroups (Table 4).
Table 3 | GMCs of anti-HBs antibodies (total vaccinated cohort)
HB-AS02 HB-AS04 GMC ratio (HB-AS02/HB-AS04)
Month Dose n GMC 95% CI Dose n GMC 95% CI Value 95% CI
Pre Pre 150 1.0 1.0–1.1 Pre 148 1.1 1.0–1.3 — —
M1 PI 150 2.6 2.0–3.4 PI 142 1.6 1.3–2.2 1.57 1.07–2.32
M2 PII 148 83.0 53.8–127.9 PII 136 7.3 5.0–10.8 11.34 6.34–20.28
M3 PII 146 108.2 73.4–159.3 PIII 134 40.1 25.4–63.4 2.70 1.49–4.89
M6 PII 144 157.1 109.1–226.2 PIII 125 45.9 30.3–69.4 3.42 1.98–5.92
M7 PIII 137 10,401.9 6286.8–17,210.7 PIV 122 666.8 405.6–1096.1 15.60 7.69–31.64
M12 PIII 125 2510.1 1509.8–4173.1 PIV 117 118.4 73.1–191.8 21.20 10.50–42.67
Abbreviations: CI, confidence interval; GMC, geometric mean antibody concentration; HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine
adjuvanted with AS04.
n is the number of subjects with available results.
Criterion for superiority is the lower limit of the 95% standardized asymptotic confidence interval for the GMC ratio 41.
%
 S
ub
jec
ts 

10
0 
m
lU
/m
l
100
80
60
40
20
0
0 1 2 3 6 7 12
Time (months)
HB-AS02 HB-AS04
Figure 2 | The proportion of subjects achieving anti-HBs
antibody concentrations of X100mIU/ml over time (total
vaccinated cohort). HB-AS02, hepatitis B virus (HBV) vaccine
adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with AS04.
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Figure 3 | Evolution of anti-HBs antibody geometric mean
concentrations (GMCs) over time with 95% confidence
intervals (CIs; total vaccinated cohort). HB-AS02, hepatitis B
virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine
adjuvanted with AS04.
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Reactogenicity and safety
Pain was the most frequently reported solicited local
symptom, occurring after 56.8% of doses in the HB-AS02
group and 38.8% of doses in the HB-AS04 group (Table 5).
The most frequently reported grade 3 local symptoms were
redness in the HB-AS02 group (occurring after 5.7% of all
doses) and pain in the HB-AS04 group (occurring after 2.9%
of all doses). Fatigue was the most frequently reported
solicited systemic symptom, occurring after 26.1% of doses
in the HB-AS02 group and 18.0% of doses in the HB-AS04
group. This was of grade 3 severity after 2.3 and 1.8% of
doses in the two groups, respectively. There was no increase
in the incidence of local and systemic symptoms after
successive doses of either vaccine. In both groups, not more
than 0.2% of doses were followed by medically attended visits
(for redness in the HB-AS02 group and redness and swelling
in the HB-AS04 group).
Unsolicited symptoms that were considered related with
vaccination were reported after 0.7% of doses in the HB-
AS02 group and 1.4% of doses in the HB-AS04 group. The
most frequently reported causally related unsolicited symp-
toms were nausea, chills, injection site hematoma, and
arthralgia in the HB-AS02 group (each reported after 0.2% of
doses) and injection-site hematoma and pruritus in the HB-
AS04 group (reported after 0.4% of doses). All causally
related unsolicited symptoms were of mild or moderate
intensity, with no grade 3 causally related unsolicited
symptoms reported in either group. During the primary
vaccination period, 124 serious adverse events (SAEs) were
reported by a total of 89 subjects (67 SAEs reported by 47
subjects in the HB-AS02 group and 57 SAEs reported by 42
subjects in the HB-AS04 group; Table 6). These were fatal in
Table 4 | Proportion of subjects seroprotected (anti-HBs antibodies X10mIU/ml), with anti-HBs antibodies X100mIU/ml and
GMCs stratified by dialysis status (total vaccinated cohort)
HB-AS02 HB-AS04
X10mIU/ml X100mIU/ml GMC X10mIU/ml X100mIU/ml GMC
Month Dose n % 95% CI % 95% CI Value 95% CI n % 95% CI % 95% CI Value 95% CI
Pre-dialysis
Pre Pre 64 0.0 0.0–5.6 0.0 0.0–5.6 1.0 1.0–1.1 62 0.0 0.0–5.8 0.0 0.0–5.8 1.0 1.0–1.0
M2 PII 63 76.2 63.8–86.0 57.1 44.0–69.5 71.3 38.2–133.2 60 41.7 29.1–55.1 18.3 9.5–30.4 9.9 5.4–18.4
M7 PIIIa 61 95.1 86.3–99.0 93.4 84.1–98.2 12,523.9 5857.8–26,775.9 54 94.4 84.6–98.8 85.2 72.9–93.4 1354.0 705.6–2598.3
M12 PIIIa 59 94.9 85.9–98.9 86.4 75.0–94.0 3161.1 1540.0–6488.7 53 88.7 77.0–95.7 77.4 63.8–87.7 255.2 132.6–491.1
Peritoneal dialysis
Pre Pre 22 0.0 0.0–15.4 0.0 0.0–15.4 1.0 1.0–1.0 20 5.0 0.1–24.9 0.0 0.0–16.8 1.2 0.9–1.6
M2 PII 22 72.7 49.8–89.3 50.0 28.2–71.8 63.6 18.1–223.0 18 38.9 17.3–64.3 27.8 9.7–53.5 11.1 2.5–48.4
M7 PIIIa 20 90.0 68.3–98.8 80.0 56.3–94.3 5508.1 938.2–32,337.6 15 100 78.2–100 73.3 44.9–92.2 616.6 183.0–2077.0
M12 PIIIa 17 82.4 56.6–96.2 82.4 56.6–96.2 1443.0 196.9–10,573.7 13 76.9 46.2–95.0 38.5 13.9–68.4 69.5 19.8–243.6
Hemodialysis
Pre Pre 64 1.6 0.0–8.4 0.0 0.0–5.6 1.1 1.0–1.2 66 6.1 1.7–14.8 0.0 0.0–5.4 1.3 1.0–1.6
M2 PII 63 79.4 67.3–88.5 55.6 42.5–68.1 105.9 52.4–214.3 58 36.2 24.0–49.9 10.3 3.9–21.2 4.7 2.9–7.6
M7 PIIIa 56 100 93.6–100 92.9 82.7–98.0 10,663.4 5189.0–21,913.7 53 86.8 74.7–94.5 64.2 49.8–76.9 331.3 140.0–784.0
M12 PIIIa 49 95.9 86.0–99.5 87.8 75.2–95.4 2304.3 1082.8–4903.9 51 68.6 54.1–80.9 56.9 42.2–70.7 61.1 27.5–135.6
Abbreviations: CI, confidence interval; GMC, geometric mean antibody concentration; HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine
adjuvanted with AS04.
n is the number of subjects with available results.
% is the percentage of subjects with defined anti-HBs antibody concentration.
aPIV in the HB-AS04 group.
Table 5 | Percentage of vaccine doses leading to solicited
local and systemic symptoms (total vaccinated cohort)
HB-AS02 HB-AS04
n % 95% CI n % 95% CI
Pain
Total 440 56.8 52.0–61.5 546 38.8 34.7–43.1
Grade 3 440 3.6 2.1–5.8 546 2.9 1.7–4.7
Redness
Total 440 39.8 35.2–44.5 546 19.8 16.5–23.4
Grade 3 440 5.7 3.7–8.3 546 0.4 0.0–1.3
Swelling
Total 440 25.9 21.9–30.3 546 15.8 12.8–19.1
Grade 3 440 2.5 1.3–4.4 546 0.5 0.1–1.6
Fatigue
Total 437 26.1 22.0–30.5 544 18.0 14.9–21.5
Grade 3 437 2.3 1.1–4.2 544 1.8 0.9–3.4
Fever
Total (X37.5 1C) 437 4.8 3.0–7.3 544 2.6 1.4–4.3
Grade 3 (439.5 1C) 437 0.2 0.0–1.3 544 0.0 0.0–0.7
Gastrointestinal symptoms
Total 437 10.1 7.4–13.3 544 7.0 5.0–9.5
Grade 3 437 0.9 0.2– 2.3 544 0.9 0.3–2.1
Headache
Total 437 10.1 7.4–13.3 544 10.1 7.7–13.0
Grade 3 437 0.5 0.1–1.6 544 1.1 0.4–2.4
Abbreviations: 95% CI, lower and upper limits of 95% confidence intervals; HB-AS02,
hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted
with AS04.
n is the total number of documented doses, and % is the percentage of doses followed
by specified symptoms.
Fever defined as oral/axillary temperature of X37.5 1C.
Grade 3 symptoms defined as redness or swelling 450mm, oral/axillary temperature
439.5 1C, or preventing normal daily activities.
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13 subjects (5 and 8 in the two groups, respectively).
However, all SAEs were considered by the investigators to be
unrelated with vaccination. For the reporting period between
month 7 and month 12, no further SAEs related with either
vaccine were retrospectively reported at month 12 (only SAEs
considered related with the study vaccine or study procedures
were to be recorded during this period).
DISCUSSION
Patients with renal insufficiency who require dialysis are
known to be at an increased risk of HBV infection and have a
suboptimal response to hepatitis B vaccination.3,19,20 At-
tempts to overcome impaired immune responses in these
patients through administration of double doses of HBV
vaccine and additional boosters have led to mixed results.
Despite vaccination with higher doses, uremic patients
respond to HBV vaccine with lower antibody concentrations,
which remain at protective levels for shorter durations than
in healthy subjects.7–9 HB-AS04 (FENDrix) is an adjuvanted
HBV vaccine licensed in Europe for use in patients with renal
insufficiency,12 developed specifically to provide higher
protection in this at-risk population. Clinical experience
shows that HB-AS04 elicits protective antibody concentra-
tions faster than double doses of conventional recombinant
HBV vaccine in uremic patients.14–17 Immune response is
also more persistent, warranting less frequent booster
vaccinations.14,15
We found three doses of HB-AS02 to induce more rapid,
enhanced, and persistent protection in pre-dialysis, perito-
neal dialysis, and hemodialysis patients than four doses of
HB-AS04. A reduction in the number of doses of HBV
vaccine required to achieve seroprotective antibody concen-
trations would clearly be of benefit to both patients and
clinicians. Seroprotection rates after only two vaccine doses
were statistically superior in the HB-AS02 group (77.0
compared with 39.0% in the HB-AS04 group). Rapid onset
of protection is of particular importance for this population
at an increased risk of HBV infection. No differences in
seroprotection rate were observed between the two groups at
month 7 (96.4% in the HB-AS02 group and 91.8% in the
HB-AS04 group). However, anti-HBs GMCs were 15-fold
higher after three doses of HB-AS02 than after four doses of
HB-AS04.
Persistence of anti-HBs is known to be closely related with
the peak antibody concentration obtained after vaccina-
tion.21–23 We found immune response to be more persistent
in the HB-AS02 group, with 93.6% of subjects remaining
seroprotected at month 12 (that is, 6 months after
completion of the primary vaccination course) compared
with only 78.6% of those in the HB-AS04 group. Because of
their impaired immune system, patients with renal insuffi-
ciency typically do not retain protective antibody levels after
vaccination and hence frequent boosters are needed to
maintain protection. Studies in hemodialysis patients have
shown that an anti-HBs concentration ofX100mIU/ml after
vaccination is necessary to maintain protective antibody
concentrations for 1 year after vaccination and to reduce the
need for additional booster doses.24–26 Indeed, this cutoff is
considered to be the best surrogate marker of long-term
seroprotection in immunocompromized patients by a
number of vaccination advisory bodies.27,28 The higher
proportion of subjects achieving anti-HBs antibody concen-
trations of X100mIU/ml after primary vaccination with the
HB-AS04 vaccine compared with a conventional recombi-
nant HBV vaccine has been shown to translate into a reduced
need for a booster dose over long-term follow-up (up to 42
months).14,15 In this study, the percentage of subjects with
anti-HBs antibody concentrations of X100mIU/ml was
increased at both months 7 and 12 in the HB-AS02 group
compared with the HB-AS04 group (91.2 versus 74.6% and
86.4 versus 64.1% at the two time points, respectively). This
suggests that longer persistence of circulating anti-HBs
antibodies may be expected in the HB-AS02 group, with an
associated further reduction in the frequency of booster
vaccination. It should be noted that six subjects in the HB-
AS04 group received a booster dose of a commercialized
HBV vaccine between the month 7 and 12 visits. No subject
in the HB-AS02 group received a booster dose. Subjects who
received an out-of-study booster were not withdrawn, but
were considered as being seronegative for anti-HBs anti-
bodies at the subsequent visit.
Additional analysis of immunogenicity was performed
according to dialysis status to check for any variation in
immune response between patients at different stages of renal
failure or receiving different types of renal replacement
therapies. Results showed the enhanced protection provided
by the HB-AS02 vaccine to be apparent in all subgroups of
uremic patients studied (pre-dialysis, peritoneal dialysis, and
hemodialysis patients). This suggests that such adjuvanted
vaccines may also be potentially useful in other types of
immunocompromized patients.
Table 6 | Nature of SAEs reported up to month 7 during the
primary vaccination study by organ class (total vaccinated
cohort)
HB-AS02 (n=151) HB-AS04 (n=149)
Total Fatal Total Fatal
All SAEs 67 5 57 8
SAEs by organ class
Cardiac 20 4 19 3
Vascular 9 1 4 2
Infectiona 10 — 14 2
Respiratory 6 — 2 —
Gastrointestinal 3 — 5 —
Change in general condition 5 — 7 —
Nervous system 3 — 2 1
Dialysis shunt/catheter
dysfunction
5 — 1 —
Neoplasm 3 — — —
Bone fracture 3 — 3 —
Abbreviations: HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-
AS04, HBV vaccine adjuvanted with AS04; SAE, serious adverse event.
aIncluding infections of the dialysis shunt/catheter.
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The observed differences in immune response induced by
the two vaccines are most likely linked with the adjuvant
used. Adjuvants have long been used to enhance the immune
response to vaccine antigens.29 Recently, novel adjuvant
systems combining classical adjuvants (such as aluminum
salts) and specific immunomodulatory molecules (such as
MPL or QS21) have been developed to optimize vaccine-
induced immune response.13 The AS04 adjuvant system
consists of MPL absorbed onto aluminum phosphate.13 MPL
is a powerful stimulant of the immune system, which acts
through binding on the Toll-like receptor 4 on antigen-
presenting cells, stimulating the maturation of these cells and
their migration to the lymph nodes. MPL-stimulated
antigen-presenting cells express increased levels of costimu-
latory molecules and secrete cytokines, inducing strong
humoral and cellular responses, depending on the antigen
considered.30,31 Dysfunctional antigen presentation has been
proposed to be the source of the impaired antibody response
to HBV vaccination in hemodialysis patients,17 with studies
showing the number, function, and maturation of antigen-
presenting cells, such as dendritic cells, to be reduced in these
patients.32–35 Toll-like receptor 4 triggering by MPL may
boost the impaired function of dendritic cells in uremic
patients.
The non-aluminum-based AS02 adjuvant system com-
bines MPL and QS21 in an oil-in-water emulsion with
synergistic immunostimulant properties.13 Adjuvant systems
containing both MPL and QS21 have previously been shown
to elicit stronger and more persistent antibody responses
against HBsAg in healthy adult volunteers than adjuvant
systems containing MPL alone.18 The AS02 adjuvant has also
been used in other candidate vaccines against complex
pathogens, including Plasmodium falciparum.13,36
Although the HB-AS02 vaccine was more reactogenic than
HB-AS04, local and systemic reactions were mainly mild to
moderate in intensity and transient in nature. Furthermore,
no increase in reactogenicity was observed after successive
doses. A significant number of subjects reported SAEs.
However, this is not unexpected in the population studied,
which is characterized by high underlying morbidity, and
none of these SAEs were considered by the investigators to be
related with vaccine. Given the improved immunogenicity
profile of HB-AS02, this slight increase in reactogenicity can
be potentially considered clinically acceptable.
In summary, a three-dose primary course of the
adjuvanted HBV vaccine HB-AS02 induces more rapid,
enhanced, and persistent protection in pre-dialysis, perito-
neal dialysis, and hemodialysis patients than a four-dose
primary course of HB-AS04 (FENDrix), an adjuvanted HBV
vaccine licensed in Europe for use in patients with renal
insufficiency.12 The higher post-vaccination GMCs for anti-
HBs antibodies and the greater proportion of subjects
achieving anti-HBs antibody concentrations of X100mIU/
ml after vaccination with HB-AS02 suggest that duration of
protection is also likely to be enhanced, potentially affording
further reductions in the need for booster doses in this at-risk
population. Such adjuvanted hepatitis B vaccines may also
have clinical utility in other categories of immunocompro-
mized patients.
MATERIALS AND METHODS
Study population
Male and female pre-dialysis (documented creatinine clearance
p30ml/min as estimated by the Cockroft–Gault formula), perito-
neal dialysis, and hemodialysis patients aged X15 years at the time
of the first vaccination were eligible for study participation. Subjects
were required to be seronegative for anti-HBs antibodies, anti-
hepatitis B core antigen antibodies, and HBsAg at study entry.
Exclusion criteria comprised: previous HBV vaccination or infec-
tion; known exposure to HBV during the previous 6 months;
confirmed or suspected human immunodeficiency virus infection; a
family history of congenital or hereditary immunodeficiency; a
history of allergic disease likely to be exacerbated by any vaccine
component; use of immunoglobulins and/or immunosuppressive
therapy (with the exception of oral steroids) within 6 months of
study entry; use of any investigational or non-registered drug or
vaccine within 30 days of the first dose of study vaccine or planned
use during the study period; and use of any other registered vaccine
within 7 days of the first vaccine dose. Pregnant and lactating
women were excluded from study participation, and women of
child-bearing potential were required to have a negative pregnancy
test and to use adequate contraception from 30 days before
vaccination to 2 months after completion of the vaccination course.
This study was sponsored by Henogen. The study was approved
by the relevant institutional ethics review boards at all participating
centers and was conducted according to the Declaration of Helsinki
Principles and Good Clinical Practice guidelines. All subjects
provided written informed consent to participate.
Study design
This was an open comparative trial conducted at 24 centers in
Belgium, Hungary, and the Czech Republic. Enrolment of subjects
was stratified according to dialysis status (pre-dialysis, hemodialysis,
or peritoneal dialysis). Within each subgroup, subjects were centrally
randomly assigned in blocks of four in a 1:1 ratio to receive either
the HB-AS02 vaccine administered according to a 0-, 1-, and 6-
month schedule or the HB-AS04 vaccine administered at 0, 1, 2, and
6 months. Subjects were followed up until 1 month after the last
vaccine dose (that is, month 7). After the primary vaccination study,
subjects were contacted at month 12 (that is, 6 months after
completion of primary vaccination) and invited to participate in a
3-year follow-up study. Preliminary results of this ongoing long-
term follow-up are presented in this study (that is, serology and
safety at month 12).
Study vaccines
Both study vaccines were manufactured by GlaxoSmithKline
Biologicals. Each 0.5ml dose of the HB-AS02V vaccine contained
AS02V (oil-in-water emulsion-based adjuvant system (50 mg
MPLþ 50 mg QS21)) and 20 mg recombinant HBsAg. Each 0.5ml
dose of the HB-AS04 vaccine (FENDrix) contained AS04 (50 mg
MPL adsorbed on aluminum salt (500 mg Al3þ )) and 20 mg
recombinant HBsAg. Both vaccines were administered as an
intramuscular injection into the deltoid region of the arm without
or least likely to be used for the arteriovenous fistula in hemodialysis
and pre-dialysis patients or the non-dominant arm in peritoneal
dialysis patients.
Kidney International (2010) 77, 247–255 253
M Surquin et al.: HB-AS02V vaccine in uremic patients o r ig ina l a r t i c l e
Immunogenicity assessments
Blood samples were obtained at months 0, 1, 2, 3, 6, 7, and 12 and
assayed for the presence of anti-HBs antibodies using a commercial
enzyme immunoassay kit (AxSYM; Abbott Laboratories, Chicago,
USA). Subjects with antibody concentrations greater than or equal
to the assay cut-off (2mIU/ml) were considered seropositive and
antibody concentrations of X10mIU/ml were considered seropro-
tective.
Reactogenicity and safety assessments
Subjects were provided with diary cards to record the occurrence of
solicited local (pain, redness, and swelling at the injection site) and
systemic (fatigue, fever, gastrointestinal symptoms, and headache)
symptoms on the day of vaccination and for 3 subsequent days.
Fever was defined as axillary or oral temperature X37.5 1C. The
intensity of solicited symptoms was rated on a scale of 0–3, with
grade 3 symptoms defined as redness or swelling 450mm in
diameter, fever439.5 1C, or as preventing normal daily activities for
all other symptoms. Unsolicited symptoms were recorded up to 30
days after each vaccine dose. SAEs were prospectively recorded
throughout the study period up to 1 month after the last vaccine
dose. After that period, only SAEs related with the study vaccines or
procedures were to be retrospectively recorded.
Statistical analysis
Anti-HBs seropositivity and seroprotection rates, the percentage of
subjects with anti-HBs antibody concentrations of X100mIU/ml,
and anti-HBs antibody GMCs were calculated with exact 95% CIs in
each treatment group at months 1, 2, 3, 6, 7, and 12.
The primary objective of this study was to show the superiority
of the HB-AS02 vaccine compared with the HB-AS04 vaccine in
terms of anti-HBs seroprotection rate (that is, the percentage of
subjects with anti-HBs antibody concentrations of X10mIU/ml) at
month 2. The primary analysis of immunogenicity was therefore
based on the total vaccinated cohort. With a sample size of 120
evaluable subjects in each group, assuming that the seroprotection
rate at month 2 would be 50% in the HB-AS04 group and at least
70% in the HB-AS02 group, the study had at least 90% power
(a¼ 0.025) to conclude superiority. Allowing for approximately
20% of subjects not to be evaluable for analysis, 150 subjects per
group (a total of 300 subjects) were planned to be enrolled.
The secondary study objectives were to explore: (1) the
superiority of the HB-AS02 vaccine at month 2 (that is, 1 month
after two doses) compared with the HB-AS04 vaccine at month 3
(that is, 1 month after three doses) in terms of anti-HBs
seroprotection rates; (2) the superiority of the HB-AS02 vaccine
compared with the HB-AS04 vaccine in terms of anti-HBs
seroprotection rates at months 1, 3, 6, and 7; (3) the superiority
of the HB-AS02 vaccine at month 2 compared with the HB-AS04
vaccine at month 3 in terms of anti-HBs GMC; and (4) the
superiority of the HB-AS02 vaccine compared with the HB-AS04
vaccine in terms of anti-HBs GMC at months 1, 2, 3, 6, and 7. The
primary objective of the long-term extension study was to evaluate
the persistence of anti-HBs antibodies at long-term time points after
primary vaccination (months 12, 24, and 36) in the according-
to-protocol cohort. However, results for the total vaccinated cohort
for month 12 are presented in this paper for consistency with
primary vaccination study.
For anti-HBs seroprotection rates, superiority was considered
met if the lower limit of the standardized asymptotic two-sided 95%
CI for the group difference (HB-AS02 group minus HB-AS04
group) in anti-HBs seroprotection rates was above zero. For anti-
HBs GMCs, superiority was computed using an analysis of variance
model on the log10 transformation of the concentrations in each
group. Superiority was considered met if the lower limit of the anti-
HBs GMC ratio between the two groups (HB-AS02 group divided
by the HB-AS04 group) was 41.
An additional analysis of immunogenicity was performed
according to dialysis status (pre-dialysis, peritoneal dialysis, and
hemodialysis) of the subjects at the time they received the first
vaccine dose.
Analysis of reactogenicity was performed on the total vaccinated
cohort. The percentage of doses followed by any solicited or unsolicited
symptoms was calculated with exact 95% CI in each group.
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